1. Home
  2. MLYS vs ESQ Comparison

MLYS vs ESQ Comparison

Compare MLYS & ESQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • ESQ
  • Stock Information
  • Founded
  • MLYS 2019
  • ESQ 2006
  • Country
  • MLYS United States
  • ESQ United States
  • Employees
  • MLYS N/A
  • ESQ N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • ESQ Commercial Banks
  • Sector
  • MLYS Health Care
  • ESQ Finance
  • Exchange
  • MLYS Nasdaq
  • ESQ Nasdaq
  • Market Cap
  • MLYS 1.0B
  • ESQ 756.3M
  • IPO Year
  • MLYS 2023
  • ESQ 2017
  • Fundamental
  • Price
  • MLYS $14.54
  • ESQ $99.25
  • Analyst Decision
  • MLYS Strong Buy
  • ESQ Hold
  • Analyst Count
  • MLYS 4
  • ESQ 3
  • Target Price
  • MLYS $27.00
  • ESQ $95.00
  • AVG Volume (30 Days)
  • MLYS 879.7K
  • ESQ 126.1K
  • Earning Date
  • MLYS 08-12-2025
  • ESQ 07-24-2025
  • Dividend Yield
  • MLYS N/A
  • ESQ 0.71%
  • EPS Growth
  • MLYS N/A
  • ESQ 13.51
  • EPS
  • MLYS N/A
  • ESQ 5.27
  • Revenue
  • MLYS N/A
  • ESQ $124,132,000.00
  • Revenue This Year
  • MLYS N/A
  • ESQ N/A
  • Revenue Next Year
  • MLYS N/A
  • ESQ $10.72
  • P/E Ratio
  • MLYS N/A
  • ESQ $18.84
  • Revenue Growth
  • MLYS N/A
  • ESQ 14.72
  • 52 Week Low
  • MLYS $8.24
  • ESQ $46.10
  • 52 Week High
  • MLYS $18.38
  • ESQ $99.75
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 50.79
  • ESQ 70.80
  • Support Level
  • MLYS $13.22
  • ESQ $93.57
  • Resistance Level
  • MLYS $14.35
  • ESQ $99.75
  • Average True Range (ATR)
  • MLYS 0.73
  • ESQ 3.05
  • MACD
  • MLYS 0.02
  • ESQ 0.66
  • Stochastic Oscillator
  • MLYS 81.12
  • ESQ 95.57

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a financial holding company. Through its subsidiary, the company operates as a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. In addition, it operates a payment processing platform through third-party independent sales organizations.

Share on Social Networks: